Clinical Trial: Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers
Study Status: NOT_YET_RECRUITING
Recruit Status: NOT_YET_RECRUITING
Condition: Urothelial Carcinoma
Study Type: INTERVENTIONAL
Official Title: A Phase 1 Trial of Naptumomab Estafenatox (NAP) in Combination With Pembrolizumab (Pembro) Preceded by Obinutuzumab (Obi) in Patients With Urothelial Cancers
Brief Summary:
The main purpose of this study is to test the safety and tolerability of naptumomab estafenatox (NAP), the planned experimental (investigational) drug, in combination with pembrolizumab following a single pretreatment with Obinutuzumab (Obi), and determine its side effects and effects on urothelial cancer.It is hypothesized that adding NAP will make pembrolizumab more effective.Participants will receive 2 infusions of Obi prior to the treatment of NAP in combination with pembrolizumab.This treatment is given in…
Read more